ConductScience.org, home

Paper36332

Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

van Hees PA and 3 others. Gut, 1979. Cited by 61 papers, by iCite.

Cite this record

ConductScience Library. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Papers, record 36332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36332

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
PubMed
Journal
Gut
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
3.74
iCite
Revised in PubMed
2019-05-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1van Hees PAP A
2Tuinte JHJ H
3van Rossum JMJ M
4van Tongeren JHJ H

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Intestinal MucosaMajor topic
SulfasalazineMajor topic
Aminosalicylic Acids
Colitis
Diarrhea
Feces
Humans
Male
Sulfapyridine
Time Factors

Source PubMed

Download CSV of topics

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
113865153Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.Lancet1962https://conductscience.org/library/papers/13865153PubMed
214218553CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.Gut1964https://conductscience.org/library/papers/14218553PubMed
314238045PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.Lancet1965https://conductscience.org/library/papers/14238045PubMed
44145285Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.Acta Pharm Suec1973https://conductscience.org/library/papers/4145285PubMed
54146996Determination of salicylazosulphapyridine in biological materials.Acta Pharm Suec1973https://conductscience.org/library/papers/4146996PubMed
64147555The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.Gut1973https://conductscience.org/library/papers/4147555PubMed
74150435A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).Gut1973https://conductscience.org/library/papers/4150435PubMed
84402886Absorption, metabolism, and excretion of salicylazosulfapyridine in man.Clin Pharmacol Ther1972https://conductscience.org/library/papers/4402886PubMed
94405598Distribution studies of salicylazosulfapyridine and its metabolites.Gastroenterology1973https://conductscience.org/library/papers/4405598PubMed
1072239An experiment to determine the active therapeutic moiety of sulphasalazine.Lancet1977https://conductscience.org/library/papers/72239PubMed
11747Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.Res Commun Chem Pathol Pharmacol1975https://conductscience.org/library/papers/747PubMed
1274700Active therapeutic moiety of sulphasalazine.Lancet1978https://conductscience.org/library/papers/74700PubMed

Download CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
18484800Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.Drugs2008https://conductscience.org/library/papers/18484800PubMed
12113642Comparative tolerability of therapies for ulcerative colitis.Drug Saf2002https://conductscience.org/library/papers/12113642PubMed
8620678The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.Clin Pharmacokinet1995https://conductscience.org/library/papers/8620678PubMed
6345112Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.Dig Dis Sci1983https://conductscience.org/library/papers/6345112PubMed
6119205Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.Eur J Clin Pharmacol1981https://conductscience.org/library/papers/6119205PubMed
6114897Sulphasalazine and male infertility: reversibility and possible mechanism.Gut1981https://conductscience.org/library/papers/6114897PubMed
6114023Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.Gut1981https://conductscience.org/library/papers/6114023PubMed
6107263Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut1980https://conductscience.org/library/papers/6107263PubMed
3780113Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.Clin Pharmacokinet1986https://conductscience.org/library/papers/3780113PubMed
3567055Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3567055PubMed
3356364Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.Gut1988https://conductscience.org/library/papers/3356364PubMed
3207553Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3207553PubMed
2878859Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.Gut1986https://conductscience.org/library/papers/2878859PubMed
28778845-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.Eur J Clin Pharmacol1986https://conductscience.org/library/papers/2877884PubMed
2864155Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet1985https://conductscience.org/library/papers/2864155PubMed
2840367Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.Gut1988https://conductscience.org/library/papers/2840367PubMed
2686883Clinical pharmacokinetic considerations in the elderly. An update.Clin Pharmacokinet1989https://conductscience.org/library/papers/2686883PubMed
2199130Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet1990https://conductscience.org/library/papers/2199130PubMed
1975737Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.Ann Rheum Dis1990https://conductscience.org/library/papers/1975737PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36332

GET https://conductscience.org/api/papers/v1/36332/authors